Phase 2 trial of the efficacy and safety of Afatinib for EGFR-TKI untreated EGFR gene mutation-Positive Elderly advanced or recurrent non-small cell lung Cancer. (APEC)

Trial Profile

Phase 2 trial of the efficacy and safety of Afatinib for EGFR-TKI untreated EGFR gene mutation-Positive Elderly advanced or recurrent non-small cell lung Cancer. (APEC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms APEC
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 31 Mar 2022 to 31 Mar 2023.
    • 23 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top